Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2005 4
2006 1
2007 3
2008 3
2009 4
2011 1
2012 2
2013 1
2014 2
2015 1
2016 2
2017 1
2018 2
2019 4
2020 1
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness and safety of vitamin D in relation to bone health.
Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, Ooi D, Atkinson S, Ward L, Moher D, Hanley D, Fang M, Yazdi F, Garritty C, Sampson M, Barrowman N, Tsertsvadze A, Mamaladze V. Cranney A, et al. Among authors: moher d. Evid Rep Technol Assess (Full Rep). 2007 Aug;(158):1-235. Evid Rep Technol Assess (Full Rep). 2007. PMID: 18088161 Free PMC article. Review.
However, most trials of higher doses of vitamin D were not adequately designed to assess long-term harms....
However, most trials of higher doses of vitamin D were not adequately designed to assess long-term harms....
Scoping reviews: time for clarity in definition, methods, and reporting.
Colquhoun HL, Levac D, O'Brien KK, Straus S, Tricco AC, Perrier L, Kastner M, Moher D. Colquhoun HL, et al. Among authors: moher d. J Clin Epidemiol. 2014 Dec;67(12):1291-4. doi: 10.1016/j.jclinepi.2014.03.013. Epub 2014 Jul 14. J Clin Epidemiol. 2014. PMID: 25034198
STUDY DESIGN AND SETTING: We summarize current understanding of scoping review publication rates, terms, definitions, and methods. We propose three recommendations for clarity in term, definition and methodology. RESULTS: We recommend adopting the terms "scoping review" or …
STUDY DESIGN AND SETTING: We summarize current understanding of scoping review publication rates, terms, definitions, and methods. We propos …
The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials.
Catalá-López F, Hutton B, Núñez-Beltrán A, Page MJ, Ridao M, Macías Saint-Gerons D, Catalá MA, Tabarés-Seisdedos R, Moher D. Catalá-López F, et al. Among authors: moher d. PLoS One. 2017 Jul 12;12(7):e0180355. doi: 10.1371/journal.pone.0180355. eCollection 2017. PLoS One. 2017. PMID: 28700715 Free PMC article.
Overall findings were limited by the clinical and methodological heterogeneity, small sample sizes of trials, short-term follow-up, and the absence of high-quality evidence; consequently, results should be interpreted with caution. ...
Overall findings were limited by the clinical and methodological heterogeneity, small sample sizes of trials, short-term follow-up, a …
Quality improvement strategies for diabetes care: Effects on outcomes for adults living with diabetes.
Konnyu KJ, Yogasingam S, Lépine J, Sullivan K, Alabousi M, Edwards A, Hillmer M, Karunananthan S, Lavis JN, Linklater S, Manns BJ, Moher D, Mortazhejri S, Nazarali S, Paprica PA, Ramsay T, Ryan PM, Sargious P, Shojania KG, Straus SE, Tonelli M, Tricco A, Vachon B, Yu CH, Zahradnik M, Trikalinos TA, Grimshaw JM, Ivers N. Konnyu KJ, et al. Among authors: moher d. Cochrane Database Syst Rev. 2023 May 31;5(5):CD014513. doi: 10.1002/14651858.CD014513. Cochrane Database Syst Rev. 2023. PMID: 37254718 Free PMC article. Review.
To explore this further, we extended the main additive model for continuous outcomes (HbA1c, SBP and LDL-C) to include an interaction term between each strategy and average baseline risk for each study (baseline thresholds were based on a data-driven approach; we used the …
To explore this further, we extended the main additive model for continuous outcomes (HbA1c, SBP and LDL-C) to include an interaction ter …
Improving the reporting of pragmatic trials: an extension of the CONSORT statement.
Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Zwarenstein M, et al. Among authors: moher d. BMJ. 2008 Nov 11;337:a2390. doi: 10.1136/bmj.a2390. BMJ. 2008. PMID: 19001484 Free PMC article.
The applicability of a trial's results (generalisability or external validity) is also important, particularly for pragmatic trials. A pragmatic trial (a term first used in 1967 by Schwartz and Lellouch) can be broadly defined as a randomised controlled trial whose purpose …
The applicability of a trial's results (generalisability or external validity) is also important, particularly for pragmatic trials. A pragm …
Comparative Effectiveness of Lipid-Modifying Agents [Internet].
Sharma M, Ansari MT, Soares-Weiser K, Abou-setta AM, Ooi TC, Sears M, Yazdi F, Tsertsvadze A, Moher D. Sharma M, et al. Among authors: moher d. Rockville (MD): Agency for Healthcare Research and Quality (US); 2009 Sep. Report No.: 09-EHC024-EF. Rockville (MD): Agency for Healthcare Research and Quality (US); 2009 Sep. Report No.: 09-EHC024-EF. PMID: 20704039 Free Books & Documents. Review.
For patients who require intensive lipid-modifying therapy, what are the comparative long-term benefits and rates of serious adverse events of coadministration of different lipid-modifying agents (i.e., a statin plus another lipid-modifying agent) compared with higher dose …
For patients who require intensive lipid-modifying therapy, what are the comparative long-term benefits and rates of serious adverse …
Enhancing the uptake of systematic reviews of effects: what is the best format for health care managers and policy-makers? A mixed-methods study.
Marquez C, Johnson AM, Jassemi S, Park J, Moore JE, Blaine C, Bourdon G, Chignell M, Ellen ME, Fortin J, Graham ID, Hayes A, Hamid J, Hemmelgarn B, Hillmer M, Holmes B, Holroyd-Leduc J, Hubert L, Hutton B, Kastner M, Lavis JN, Michell K, Moher D, Ouimet M, Perrier L, Proctor A, Noseworthy T, Schuckel V, Stayberg S, Tonelli M, Tricco AC, Straus SE. Marquez C, et al. Among authors: moher d. Implement Sci. 2018 Jun 22;13(1):84. doi: 10.1186/s13012-018-0779-9. Implement Sci. 2018. PMID: 29929538 Free PMC article. Review.
Metformin monotherapy for type 2 diabetes mellitus.
Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Saenz A, et al. Among authors: moher d. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD002966. doi: 10.1002/14651858.CD002966.pub3. Cochrane Database Syst Rev. 2005. PMID: 16034881 Updated. Review.
BACKGROUND: Metformin is an anti-hyperglycaemic agent used for the treatment of type 2 diabetes mellitus. Type 2 diabetes may present long-term complications: micro- (retinopathy, nephropathy and neuropathy) and macrovascular (stroke, myocardial infarction and peripheral v …
BACKGROUND: Metformin is an anti-hyperglycaemic agent used for the treatment of type 2 diabetes mellitus. Type 2 diabetes may present long- …
34 results